---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019700"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2023-12-08T23:59:59+00:00"
generated_at: "2026-06-07T15:28:47.359929+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences exchanges Series 1 Preferred for Series 2 at 60:1; no Series 1 outstanding

## Summary
- 70,000,000 Series 1 Preferred exchanged for 1,166,667 Series 2 Preferred (60:1 ratio).
- Series 2 Preferred automatically converts into Common upon $14M+ equity financing (Mandatory Conversion Event).
- Prior nine-month financing limitation terminates as of December 4, 2023.
- Amended articles to create Series 2; rights substantially similar to Series 1 except conversion trigger.
- Holders include Crocker Mountain, Kraft entities, McCance Trust, and others.

## SEC filing metadata
- accession: 0001558370-23-019700
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2023-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837023019700/0001558370-23-019700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837023019700/pmn-20231204x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019700
- JSON: https://secwatch.observer/filing/0001558370-23-019700.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019700.txt

## Key facts
- Governance Changes
  ProMIS Neurosciences Inc.: The Company filed articles of amendment to create a new class of Series 2 Preferred Shares, effective December 4, 2023 (effective 2023-12-04).
  - Change: charter amendment
  - Effective: 2023-12-04
  source text: Effective as of December 4, 2023, the Company filed articles of amendment (the “ Articles of Amendment ”) to amend its articles to create the new class of Series 2 Preferred Shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000155837023019700/0001558370-23-019700-index.htm
- Material Agreements
  ProMIS Neurosciences Inc. entered into Exchange Agreement with the holders of the Company's Series 1 convertible preferred shares (effective 2023-12-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the holders of the Company's Series 1 convertible preferred shares
  - Effective: 2023-12-04
  source text: On December 4, 2023, Promis Neurosciences, Inc. (the “ Company ”) entered into a Share Exchange Agreement (the “ Exchange Agreement ”) with the holders (the “ Holders ”) of the Company’s Series 1 convertible preferred shares (the “ Series 1 Preferred Shares ”), pursuant to which the Series 1 Preferred Shares were exchanged for a new class of Series 2 convertible preferred shares (the “ Series 2 Preferred Shares ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000155837023019700/0001558370-23-019700-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.